EcoDrugPlus

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSPREG00000021795
Gene Symbol: GRIA3
3 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSPREG00000003014
Gene Symbol: GRIN1
3 Cross references
176 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSPREG00000018839
Gene Symbol: GRIN2A
3 Cross references
228 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSPREG00000016322
Gene Symbol: GRIN2B
3 Cross references
255 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSPREG00000012992
Gene Symbol: GRIN2C
3 Cross references
115 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSPREG00000009399
Gene Symbol: GRIN2C
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSPREG00000005322
Gene Symbol: GRIN3A
4 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSPREG00000005839
Gene Symbol: GRIN3B
3 Cross references
222 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSPREG00000013680
Gene Symbol: GRIK1
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSPREG00000012879
Gene Symbol: GRIK1
3 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSPREG00000017794
Gene Symbol: GRIK2
4 Cross references
241 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSPREG00000006189
Gene Symbol: GRIK2
3 Cross references
253 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).